Drug Eluting Balloons Market Insights
The drug eluting balloons market is projected to grow at an exponential CAGR over the coming years. The increasing investments made in the healthcare sector of Asia Pacific coupled with the demand for technologically advanced products in the European and North American region is expected to positively influence market growth over the coming years.
The increasing preference given to minimal invasive surgeries is expected to augment market demand. Similarly, increasing demand for cath labs that conduct diagnostic as well as therapeutic procedures is expected to foster need for drug eluting balloons. Drug eluting balloons provide a higher level of safety as compared to other treatment options. Minimal invasive surgeries are preferred due to their faster recovery time, lower post surgery infections & complications, and lower incision marks.
Drug Eluting Balloons Market: Product Insights
On the basis of product, the drug eluting balloons market is segmented into peripheral DEBs and coronary DEBs. The coronary DEB segment includes used of these devices for in-stent re-stenosis, bifurcation lesions, acute myocardial infarction, and treating lesions in tortuous vessels. The peripheral segment includes treatment of femoral/popliteal lesions and below knee lesions. The peripheral DEB segment occupied a large share in the market in 2016. This segment is also projected to register a high CAGR from 2017 to 2025 on account of FDA approvals and rising research investments.
Drug Eluting Balloons Market: End-user Insights
On the basis of end-users, the drug eluting balloons market is segmented into cath labs, hospitals, and ambulatory surgical centers. The cath labs segment is expected to grow at a high CAGR on account of increasing investments in establishing cath labs in developing economies. The growing investments made in healthcare infrastructure development are also expected to augment market growth over the coming years.
Drug Eluting Balloons Market: Regional Insights
Drug eluting balloons are anticipated to gain preference in the U.S. on account of rising prevalence of coronary diseases. FDA approvals given to drug eluting balloons in this region is expected to positively influence market growth over the coming years.
Rising investments in developing healthcare capabilities in the Asia Pacific region is expected to augment market growth. Increasing risk of complications in open heart surgeries has led to the preference for minimal invasive surgeries which use drug eluting balloons. Growing investments by major manufacturers in research & development activities has led to new product launches.
Drug Eluting Balloons Market: Vendor Landscape
The report contains a chapter dedicated to vendors operating in the market, covering raw material manufactures, equipment developers, manufacturers, and distributors. The report provides these insights on a regional level. This section of the report entails contact details, experience, products manufactured/supplied, and geographical presence of companies.
Drug Eluting Balloons Market: End-Use Landscape
The report provides a detailed list of end-users operating across the world. The end-user landscape includes consumer contact details, geographical presence, revenue, product portfolio, organic and inorganic growth strategies among others. Some of the companies who are likely to use drug eluting balloons includeWellspan York Hospital, Beth Israel Deaconess Medical Center,and NewYork–Presbyterian Hospital among others.
Drug Eluting Balloons Market Share & Competitor Analysis
Prominent companies catering to the drug eluting balloons market include Medtronic, Boston Scientific, Cook Medical, C.R. Bard, B. Braun Melsungen, Eurocor GmbH, Aachen Resonance GmbH, Cardionovum, Wellinq, Spectranetics, and Acrostakamong others
Avail customized purchase options to meet your exact research needs: